Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Nyxoah S A (NYXH)

Nyxoah S A (NYXH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 235,932
  • Shares Outstanding, K 24,940
  • Annual Sales, $ 4,710 K
  • Annual Income, $ -46,770 K
  • EBIT $ -51 M
  • EBITDA $ -49 M
  • 60-Month Beta 1.45
  • Price/Sales 53.72
  • Price/Cash Flow N/A
  • Price/Book 1.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.46
  • Number of Estimates 4
  • High Estimate -0.39
  • Low Estimate -0.51
  • Prior Year -0.29
  • Growth Rate Est. (year over year) -58.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.50 +11.29%
on 10/03/24
10.12 -6.52%
on 10/09/24
-0.24 (-2.47%)
since 09/27/24
3-Month
7.33 +29.06%
on 09/09/24
10.12 -6.52%
on 10/09/24
+1.34 (+16.50%)
since 07/29/24
52-Week
4.00 +136.50%
on 01/17/24
20.00 -52.70%
on 03/18/24
+3.64 (+62.40%)
since 10/27/23

Most Recent Stories

More News
Nyxoah S.A. (NYXH) Q2 2022 Earnings Call Transcript

NYXH earnings call for the period ending June 30, 2022.

NYXH : 9.46 (-2.87%)
Nyxoah Reports Second Quarter and First Half 2022 Financial and Operating Results

REGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2022 Financial and Operating Results DREAM enrollment complete, 12-month clinical data...

NYXH : 9.46 (-2.87%)
Nyxoah and Acurable Enter into Distribution Agreement in Germany for the AcuPebble SA100 Home Sleep Test

Nyxoah and Acurable Enter into Distribution Agreement in Germany for the AcuPebble SA100 Home Sleep Test Mont-Saint-Guibert, Belgium – August 2, 2022,...

NYXH : 9.46 (-2.87%)
Nyxoah to Present at the Canaccord Genuity 42nd Annual Growth Conference

Nyxoah to Present at the Canaccord Genuity 42nd Annual Growth Conference Mont-Saint-Guibert, Belgium – July 27, 2022, 10:30pm CET / 4:30pm ET –...

NYXH : 9.46 (-2.87%)
Nyxoah to Release Second Quarter and First Half 2022 Financial Results on August 8, 2022

Nyxoah to Release Second Quarter and First Half 2022 Financial Results on August 8, 2022 Mont-Saint-Guibert, Belgium – July 19, 2022, 10:30pm CET /...

NYXH : 9.46 (-2.87%)
Nyxoah Announces CE Mark Approval for Genio® 2.1

Nyxoah Announces CE Mark Approval for Genio® 2.1 The next generation external activation chip leverages Nyxoah’s scalable platform to continuously...

NYXH : 9.46 (-2.87%)
Nyxoah Receives FDA IDE Approval to Initiate the ACCCESS Study of Genio® in Complete Concentric Collapse Patients

REGULATED INFORMATIONINSIDE INFORMATION Nyxoah Receives FDA IDE Approval to Initiate the ACCCESS Study of Genio® in Complete Concentric Collapse...

NYXH : 9.46 (-2.87%)
Information on the total number of voting rights and shares

REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), June 30, 2022, 10:30 pm CET / 4:30 pm...

NYXH : 9.46 (-2.87%)
Nyxoah Joins the Euronext Tech Leaders Initiative, Included in the Euronext Tech Leaders Index

Nyxoah Joins the Euronext Tech Leaders Initiative, Included in the Euronext Tech Leaders Index Mont-Saint-Guibert, Belgium – June 7, 2022 4:30pm ET /...

NYXH : 9.46 (-2.87%)
FDA Approves Genio® 2.1 For Use in DREAM U.S. IDE Pivotal Study

FDA Approves Genio® 2.1 For Use in DREAM U.S. IDE Pivotal Study  New smartphone application, upgraded activation chip, improved user interface, and...

NYXH : 9.46 (-2.87%)

Business Summary

Nyxoah SA is a medical technology company. It focused on the development and commercialization of solutions to treat Obstructive Sleep Apnea. Nyxoah SA is based in Belgium.

See More

Key Turning Points

3rd Resistance Point 9.86
2nd Resistance Point 9.73
1st Resistance Point 9.59
Last Price 9.46
1st Support Level 9.32
2nd Support Level 9.19
3rd Support Level 9.05

See More

52-Week High 20.00
Fibonacci 61.8% 13.89
Fibonacci 50% 12.00
Fibonacci 38.2% 10.11
Last Price 9.46
52-Week Low 4.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar